Inteum Company
Links
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - therapeutics+%3e+infectious+diseases
53
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Antiviral Compounds Inhibiting Mpox Virus, and Methods and Mpox Treatment Thereof (UCLA Case No. 2025-037)
UCLA researchers from the Department of Molecular and Medical Pharmacology have identified potent drug candidates inhibiting monkeypox virus, which may be used as therapies to prevent or treat viral infections. BACKGROUND: Monkeypox (mpox) is a viral infection related to smallpox that manifests as a rash, lesions, swollen lymph nodes, and flu-like...
Published: 10/22/2025
|
Inventor(s):
Vaithilingaraja Arumugaswami
,
Robert Damoiseaux
Keywords(s):
Category(s):
Therapeutics > Infectious Diseases
Antiviral Compounds Inhibiting Zika Virus (ZIKV), and Methods and Zika Treatment Thereof (UCLA Case No. 2025-241)
UCLA researchers from the Molecular and Medical Pharmacology Department and CNSI have identified antiviral compounds that effectively inhibit Zika virus infection and cytopathic effects, potentially leading to improved therapeutics and treatment outcomes. BACKGROUND: Zika virus (ZIKV), a flavivirus now endemic to several regions globally, can cause...
Published: 10/3/2025
|
Inventor(s):
Vaithilingaraja Arumugaswami
,
Robert Damoiseaux
Keywords(s):
Category(s):
Life Science Research Tools > Screening Libraries
,
Diagnostic Markers > Immunology
,
Diagnostic Markers > Targets And Assays
,
Therapeutics > Infectious Diseases
,
Therapeutics > CNS and Neurology
,
Therapeutics > Immunology And Immunotherapy
,
Platforms > Diagnostic Platform Technologies
Structure-Based Design of Antisense Oligonucleotide Drugs (UCLA Case No. 2020-916)
UCLA researchers led by Professor Feng Guo have developed a next-generation platform for designing antisense oligonucleotide (ASO) therapeutics using RNA structure as a blueprint, achieving enhanced specificity, efficacy, and versatility for the treatment of a wide spectrum of genetic and infectious diseases. INNOVATION: UCLA researchers in the Department...
Published: 9/12/2025
|
Inventor(s):
Feng Guo
,
Vaithilingaraja Arumugaswami
Keywords(s):
Category(s):
Platforms
,
Therapeutics > Infectious Diseases
,
Therapeutics > Genetic Diseases
Inhalational Therapy for Tuberculosis and Mycobacterial Lung Disease (UCLA Case No. 2025-278)
UCLA researchers from the Department of Medicine have identified drug combinations that can speed up treatment of tuberculosis by being delivered intranasally as well as orally. BACKGROUND: Tuberculosis (TB) is an airborne disease caused by the bacterium Mycobacterium tuberculosis, affecting more than 10 million people worldwide each year. The standard...
Published: 8/13/2025
|
Inventor(s):
Marcus Horwitz
,
Bai Yu Clemens
,
Daniel Clemens
Keywords(s):
Category(s):
Platforms > Drug Delivery
,
Therapeutics > Infectious Diseases
,
Therapeutics > Respiratory And Pulmonary
Engineered Mucosal-Associated Invariant T (MAIT) Cells and Methods of Making and Using Thereof (UCLA Case No. 2024-055)
UCLA researchers in the Department of Microbiology Immunology and Molecular Genetics have developed a novel platform and methodology for the production of mucosal-associated invariant T (MAIT) cells for therapeutic use in infectious diseases, autoimmune disorders, and cancer. BACKGROUND: Mucosal-associated invariant T (MAIT) cells are a subset of...
Published: 7/31/2025
|
Inventor(s):
Lili Yang
Keywords(s):
Category(s):
Therapeutics > Oncology
,
Therapeutics > Infectious Diseases
,
Therapeutics > Immunology And Immunotherapy
,
Therapeutics > Autoimmune
Targeting Plasma Extracellular Vesicles as Therapy for Severe Bacterial Pneumonia (UCLA Case No. 2025-274)
UCLA researchers in the Department of Anesthesiology & Perioperative Medicine have identified a novel method of targeting plasma extracellular vesicles to help suppress inflammation and infection during severe bacterial pneumonia. BACKGROUND: Direct and indirect lung injury such as through pneumonia or following abdominal infections can lead to...
Published: 7/17/2025
|
Inventor(s):
Jae Woo Lee
Keywords(s):
Category(s):
Therapeutics > Infectious Diseases
,
Therapeutics > Inflammation And Inflammatory Diseases
,
Therapeutics > Respiratory And Pulmonary
Use of Endogenous Plasma Extracellular Vesicles as an Adjuvant Therapeutic for Pneumonia (UCLA Case No. 2025-236)
UCLA researchers in the Department of Anesthesiology & Perioperative Medicine have developed a novel therapeutic approach using human extracellular vesicles (EVs) to block harmful effects of bacterial outer membrane vesicles (OMVs) in Pseudomonas aeruginosa pneumonia. This strategy aims to reduce inflammation, disrupt bacterial communication, and...
Published: 7/17/2025
|
Inventor(s):
Jae Woo Lee
Keywords(s):
Category(s):
Therapeutics > Respiratory And Pulmonary
,
Therapeutics > Infectious Diseases
Reverse Engineering Vaccine Antigens (UCLA Case No. 2025-074)
UCLA researchers from the Department of Pediatrics-Allergy/Immunology have developed a novel platform to reverse engineer vaccine antigens for the prevention and treatment of infectious disease and cancer. BACKGROUND: Vaccines function by introducing antigens into a host to stimulate an immune response, providing protection against pathogens and certain...
Published: 7/17/2025
|
Inventor(s):
Manish Butte
Keywords(s):
Category(s):
Therapeutics > Oncology
,
Therapeutics > Infectious Diseases
,
Therapeutics > Vaccines
An Alternative T Cell Redirecting Bispecific Antibody Against Human Cytomegalovirus (UCLA Case No. 2024-198)
UCLA researchers in the Department of Microbiology Immunology and Molecular Genetics have created a novel T cell redirecting bispecific antibody (TRBA) for treatment of cytomegalovirus (CMV) infection. BACKGROUND: The human cytomegalovirus (CMV) has a seroprevalence of about 60% in the USA and nearly 100% of the population in some parts of the world....
Published: 7/17/2025
|
Inventor(s):
Otto Yang
Keywords(s):
Anti-CD3 antibodies
,
Bispecific antibodies
,
CD8 T cells
,
Human cytomegalovirus (CMV)
,
immunocompromised patients
,
Immunotherapy
,
Lymphocytes
,
T cell redirecting bispecific antibody (TRBA)
,
Transplant
,
Viral infection
Category(s):
Therapeutics > Infectious Diseases
,
Therapeutics > Immunology And Immunotherapy
Novel Host-Directed Therapeutic Agent to Cure Infectious Diseases (UCLA Case No. 2023-079)
UCLA researchers in Department of Molecular and Medical Pharmacology, in collaboration with Hannover Medical School in Germany, have developed a host-directed therapeutic agent targeting mammalian deoxycytidine kinase to prevent, treat, and even cure any local and systemic infectious diseases in human and animal hosts. BACKGROUND: Many clinically...
Published: 7/17/2025
|
Inventor(s):
Caius Radu
,
Evan Abt
,
Volker Achim Winstel
Keywords(s):
Category(s):
Therapeutics > Infectious Diseases
1
2
3
4
5
6